Trial
Neurology

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

Trial
Neurology

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Trial
Neurology

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

News

Durbin visits Simmons Cancer Institute to discuss nationwide shortage of cancer drugs

Senator Dick Durbin held a news conference at SIU's Simmons Cancer Institute to discuss the shortage of life-saving drugs for cancer patients. Last month, Durbin urged the FDA to use the agency’s authority to immediately address the ongoing shortage.
News

Durbin visits Simmons Cancer Institute to discuss nationwide shortage of cancer drugs

Senator Dick Durbin held a news conference at SIU's Simmons Cancer Institute to discuss the shortage of life-saving drugs for cancer patients. Last month, Durbin urged the FDA to use the agency’s authority to immediately address the ongoing shortage.
News

Durbin visits Simmons Cancer Institute to discuss nationwide shortage of cancer drugs

Senator Dick Durbin held a news conference at SIU's Simmons Cancer Institute to discuss the shortage of life-saving drugs for cancer patients. Last month, Durbin urged the FDA to use the agency’s authority to immediately address the ongoing shortage.
News

Durbin visits Simmons Cancer Institute to discuss nationwide shortage of cancer drugs

Senator Dick Durbin held a news conference at SIU's Simmons Cancer Institute to discuss the shortage of life-saving drugs for cancer patients. Last month, Durbin urged the FDA to use the agency’s authority to immediately address the ongoing shortage.
News

ALS drug shows varying effects against Alzheimer’s, metabolism

Effects are unique between males and females A recent study from the Hascup labs at SIU Medicine has shown how riluzole, a drug compound typically used to treat amyotrophic lateral sclerosis (ALS), showed different effects on models with Alzheimer’s disease (AD) depending on whether they were male or female. Published in the Journal of Alzheimer’s Disease , the study reports male mouse models with Alzheimer’s and healthy models showed improved glucose tolerance with riluzole treatment. However, female mouse models with Alzheimer's disease did not show significant improvements in metabolism
Events

Hiring Event

Did you know the average person will spend over 90,000 hours at work in their lifetime? Why not spend it at a place you love with a mission you can believe in? At SIU Medicine, we're committed to helping people in central and southern Illinois meet their health care needs through patient care, service to the community, education and research. Learn why so many love working at SIU Medicine: Join us at an open-house hiring event on Thursday, April 6, at the SIU Medicine Administrative Offices, 201 E. Madison, Springfield. Select positions can earn up to $10,000 in sign-on bonuses! We're looking
News

Group wins international sim training contest

SIU surgeon Melanie Barnard, MD, was part of an international team of clinicians who won the $700,000 grand prize to design low-cost simulation surgical training in the Global Surgical Training Challenge.
Subscribe to Research